Tests added vein isolation with pulsed field ablation for irregular heartbeat
Compares two heart procedures in adults with paroxysmal atrial fibrillation, an irregular heartbeat.
Plain-language title generated from the registry record
Registry title: Pulsed Field Ablation of SVC and PV in Paroxysmal Atrial Fibrillation (PASPA Study)
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07191626, who can take part
Where in China
- The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital). No. 168, Changhai Road, Yangpu District, Shanghai, China.Shanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Changhai Hospital
- Trial code
- NCT07191626
- Record updated
- 25 September 2025
- Original description
The PASPA study is a multicenter, randomized trial comparing Pulmonary Vein Isolation (PVI) alone versus PVI plus Superior Vena Cava Isolation (SVCI) using Pulsed Field Ablation (PFA) in patients with paroxysmal atrial fibrillation (PAF).Read full original descriptionShow less
Pulsed Field Ablation of Superior Vena Cava in Addition to Pulmonary Vein in Paroxysmal Atrial Fibrillation: A Multicenter Randomized Controlled Trial (PASPA Study)
The PASPA study is a multicenter, randomized trial comparing Pulmonary Vein Isolation (PVI) alone versus PVI plus Superior Vena Cava Isolation (SVCI) using Pulsed Field Ablation (PFA) in patients with paroxysmal atrial fibrillation (PAF).
650 participants will be followed for 12 months. The main goal is to see if adding SVCI reduces arrhythmia recurrence without increasing complications such as phrenic nerve injury or sinus node dysfunction.
Inclusion: Documented paroxysmal AF (episodes self-terminating within 7 days), evidenced by ECG, Holter, or event monitor; Age between 18 and 80 years; Willing and able to provide written informed consent.
Exclusion: Absolute contraindication to anticoagulation therapy; Stroke or myocardial infarction within 1 month prior to enrollment; Previous atrial fibrillation ablation procedure; Intracardiac thrombus (left atrium or left atrial appendage); Left atrial anterior-posterior diameter > 60 mm; Uncontrolled hyperthyroidism; Pregnancy or planning pregnancy; Life expectancy less than 1 year; Known or suspected AF triggers primarily originating from the SVC (based on pre-procedure mapping, if available); Inability or unwillingness to participate in the study or comply with follow-up requirements.